Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

More than ever before, nurse practitioners are prescribing medications. Thousands of NPs and PAs have outpatient clinics in Texas that formerly required a physician to be on site full time. That change brings up another question that researchers continue to ask: Do the model’s predictions hold on safety. The answer depends heavily on how collaboration […]

The post How Physician Oversight Shapes Nurse-Led Clinics appeared first on Medical News Bulletin.

Heidi Overton, MD, PhD, has been nominated to lead the FDA.
The pick from President Donald J. Trump comes months after Martin Makary, MD, resigned from the position in May.
Trump made the announcement in a Truth Social post Wednesday, calling Overton “a ROCKSTAR” in the administration, “where she has worked directly with Secretary Kennedy, Dr. Oz, and team, to deliver on the MOST TRANSFORMATIVE Health Agenda in History.”
Overton is currently deputy assistant to the president for domestic policy. She previously served as a White House fellow in Trump’s first term and chief policy officer and vice

The FDA granted 510(k) clearance to Zeiss Clinic 360, a cloud-based tool for managing and tracking patient data in eye care, according to Zeiss.
The software is expected to be available in the U.S. in the early fall through a subscription.
Zeiss Clinic 360 works in a web browser and aims to give a “comprehensive patient view” by bringing together data from diagnostic devices, electronic medical records and other practice systems, according to the company. It analyzes trends in clinical data and can be used to track progression of glaucoma and other diseases.
“Clinic 360 is designed to be vendor

PARK CITY, Utah — According to data presented at the International Extreme Sports Medicine Congress, published literature on dietary supplements tends to be low quality and often funded by manufacturers, making its use “a bit of a gamble.”
“Even though people look to the literature for dietary supplements, which is a good thing to do rather than going with your gut, a lot of the evidence is biased and some of the science is particularly low quality,” Nicholas B. Tiller, PhD, research associate at the Lundquist Institute at Harbor-UCLA Medical Center and author of

CMS has updated its guidance on prior authorization metrics reporting, addressing the AMA’s concerns about how health insurers were disclosing requirements and outcomes, according to the organization.
The AMA said it notified CMS about issues with reporting metrics after it conducted a review examining how 15 Medicare Advantage contracts were abiding by the transparency requirements from CMS’s 2024 Interoperability and Prior Authorization final rule.
The review showed that “on the surface, many plans appeared to comply with the rule while presenting disclosures in places and formats that made

Tarsus Pharmaceuticals is entering the retina space with deals to acquire Alkeus Pharmaceuticals and iRenix Medical, according to press releases.
The acquisitions are focused on two therapies: gildeuretinol (ALK-001, Alkeus Pharmaceuticals) and IRX-101 (iRenix Medical). Gildeuretinol is an investigational once-daily oral therapy for the treatment of Stargardt disease designed to reduce damage to the retina caused by the accumulation of toxic dimers, while IRX-101 is an investigational ocular antiseptic designed to reduce pain and corneal toxicity after intravitreal injections, according to

A phase 3 trial found that a combination of intismeran autogene plus pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with high-risk melanoma, according to topline data from the manufacturer.
The randomized, double-blind INTerpath-001 trial evaluated intismeran autogene (intismeran; Merck, Moderna), an investigational mRNA-based individualized neoantigen therapy, and pembrolizumab (Keytruda, Merck) vs. pembrolizumab monotherapy among 1,137 patients with completely resected stage IIB-IV melanoma.
A pre-specified interim analysis showed that the combination

For individuals with coexisting atrial fibrillation and Alzheimer’s disease, non-vitamin K anticoagulants may be associated with slower cognitive decline in addition to better safety outcomes, according to a longitudinal study.
Data published in European Heart Journal showed significantly slower cognitive declines among users of more modern non-vitamin K anticoagulants (NOACs) compared with users of warfarin and those who did not use any anticoagulants, wrote Maria Eriksdotter, MD, PhD, professor of geriatrics, and Nanbo Zhu, PhD, MSc, postdoctoral researcher, both with Karolinska Institutet,

As I sat down in one of our Out-Around-The-Deck* chairs, my two Aussies, Sasha and Bohdi, trotted over to see what Papi was up to. Doubtless that can of sparkling water sitting just next to me must mean doggie snacks, right?
Discovering that it was just bubbles, they nonetheless curled up in the shade of my umbrella and instantly fell asleep.
Aussies don’t think when they sits. They sleeps.
As for me, well Bunky, I admit that sometimes I do, indeed, just sit. Especially when my inland sea sits calmly, unruffled, from just beyond Sasha’s tail to the horizon. But not today. Much has happened since

A global consortium of health care professionals and patients unveiled a new name for polycystic ovary syndrome that could transform how the condition is viewed, studied and treated in the years ahead.
In May, a paper published by a global consortium in The Lancet announced the name for polycystic ovary syndrome, commonly known as PCOS, would be changed to polyendocrine metabolic ovarian syndrome, or PMOS.
Image: Nanette Santoro, MD
PCOS/PMOS is a common health condition that affects one in eight women.
The name PCOS was based on the macroscopic appearance of ovaries among women with the